drugset / Trial / NCT00368186
Immunogenicity and Safety Study of Pneumococcal 7-Valent Conjugate Vaccine in Sickle Cell Disease Infants.
Non-randomizedSingle-groupOpen-labelPrevention
Summary
The primary objectives of this study were to assess the immunogenicity and the tolerance of the heptavalent pneumococcal conjugate vaccine (Prevenar) in young infants (2 months of age) with sickle cell disease when administred at 2,3, and 4 months of age.
Timeline
- Start
- 2001-05
- Primary completion
- —
- Completion
- 2002-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pneumovax 23 | Vaccine | — | — |